EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, PRTA: Prothena Corp

22 Oct 25 15:59
LAST:

9.890

CHANGE:
 0.34		OPEN:
10.670		HIGH:
10.830		ASK:
63.500		VOLUME:
264.0K
CHG(%):
3.28		PREV:
10.215		LOW:
9.720		BID:
60.400		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
22 Oct 2510.22010.3509.7209.880429.4K
21 Oct 2510.37010.61010.18010.215289.8K
20 Oct 2510.05010.5509.95510.370558.9K
17 Oct 259.99010.2309.6109.920777.3K
16 Oct 2510.76010.90010.03010.090624.8K
15 Oct 2510.12010.72010.12010.660801.9K
14 Oct 2510.32010.32010.03210.120392.0K
13 Oct 2510.03010.35010.00010.350703.1K
10 Oct 2510.34010.4509.98010.050734.0K
09 Oct 2510.43010.65010.28010.300801.3K

COMPANY PROFILE

Name:Prothena Corp
About:Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Sector:Healthcare
Industry:Biotechnology
Address:77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60
Website:https://www.prothena.com
CUSIP:G72800108
CIK:0001559053
ISIN:USG728001086
FIGI:BBG003PDKJF7

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:10.102.1%
MA10:10.203.1%
MA20:10.021.3%
MA50:9.029.6%
MA100:7.6529.3%
MA200:9.632.7%
STO14:1.92 
RSI14:48.50
WPR14:-97.50 
MTM14:-0.04
ROC14:0.00 
ATR:0.51 
Week High:10.9010.2%
Week Low:9.612.9%
Month High:10.9010.2%
Month Low:8.022.7%
Year High:18.8890.9%
Year Low:4.32128.9%